Researchers are installing safety switches and adding other features to the immune therapy
Eye of Science/Science Source
This wasn’t 15-year-old Connor McMahon’s first time in the hospital. But the 107° fever he’d been running for three days had his dad frightened. The teen was hallucinating, talking gibberish and spouting curses.
“I thought he was going to die,” says Connor’s father, Don McMahon, who stayed close as his son received and recovered from an experimental treatment for leukemia. “It was really hard to watch.” But the fever finally broke, and Connor returned home. Just a month later, in November 2016, he was cancer-free and back on the ice in his hockey skates and pads.
That episode was Connor’s third bout with acute lymphoblastic leukemia. The experimental treatment was a last hope for the boy, who was first diagnosed at age 3. He has spent a total of six years of his life receiving chemotherapy. When the cancer came back in 2016, the doctors said the prognosis wasn’t good.
At that point, “it was about